Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

NCT03783923 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT03783923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03783923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2019
Completion date
January 1, 2021
Enrollment
11 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

limb-girdle muscular dystrophy